<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="[g], [h], â�ŽCorresponding authors at: State Key Laboratory of Emerging" exact="Infectious" post="Diseases, Carol Yu Centre for Infection, Department of Microbiology,"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="the COVID-19 resource centre remains active. Graphical abstract Abstract Coronavirus" exact="Disease" post="2019 (COVID-19) caused by the emerging severe acute respiratory"/>
 <result pre="Abstract Coronavirus Disease 2019 (COVID-19) caused by the emerging severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a"/>
 <result pre="Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude"/>
 <result pre="Disease 2019 (COVID-19) caused by the emerging severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is associated with a crude case"/>
 <result pre="small number of patients. However, their clinical use may be" exact="limited" post="by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that"/>
 <result pre="RNA viruses that have repeatedly crossed species barriers to cause" exact="disease" post="in human and animals [1]. In the past two"/>
 <result pre="novel human-pathogenic coronaviruses have emerged to cause epidemics of severe" exact="respiratory" post="infection among human, including severe acute respiratory syndrome coronavirus"/>
 <result pre="human-pathogenic coronaviruses have emerged to cause epidemics of severe respiratory" exact="infection" post="among human, including severe acute respiratory syndrome coronavirus (SARS-CoV)"/>
 <result pre="cause epidemics of severe respiratory infection among human, including severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle East respiratory"/>
 <result pre="epidemics of severe respiratory infection among human, including severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2003, Middle East respiratory syndrome"/>
 <result pre="of severe respiratory infection among human, including severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2003, Middle East respiratory syndrome coronavirus"/>
 <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) since 2012, and most recently SARS-CoV-2"/>
 <result pre="acute respiratory syndrome coronavirus (SARS-CoV) in 2003, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) since 2012, and most recently SARS-CoV-2 since"/>
 <result pre="months, the number of patients with SARS-CoV-2 infection, or Coronavirus" exact="Disease" post="2019 (COVID-19), has exceeded the total number of cases"/>
 <result pre="SARS-CoV-2 infection, or Coronavirus Disease 2019 (COVID-19), has exceeded the" exact="total" post="number of cases of SARS and MERS by nearly"/>
 <result pre="globally [5]. The clinical severity of COVID-19 ranges from asymptomatic" exact="infection" post="to fatal disease. The disease is usually mild in"/>
 <result pre="of COVID-19 ranges from asymptomatic infection to fatal disease. The" exact="disease" post="is usually mild in children, but severe infection in"/>
 <result pre="disease. The disease is usually mild in children, but severe" exact="infection" post="in immunocompromised and elderly patients may be associated with"/>
 <result pre="% [[6], [7], [8]]. Patient with severe COVID-19 may develop" exact="acute" post="respiratory distress syndrome, multiorgan dysfunction syndrome, and other extrapulmonary"/>
 <result pre="[[6], [7], [8]]. Patient with severe COVID-19 may develop acute" exact="respiratory" post="distress syndrome, multiorgan dysfunction syndrome, and other extrapulmonary manifestations"/>
 <result pre="or antiviral for treatment and prophylaxis. Similar to other emerging" exact="viral" post="infections, the de novo development of antiviral drugs would"/>
 <result pre="hydroxychloroquine are mildly immunosuppressive drugs used in the treatment of" exact="autoimmune diseases" post="and malaria that exhibited 50 % maximal effective concentration"/>
 <result pre="immunosuppressive drugs used in the treatment of autoimmune diseases and" exact="malaria" post="that exhibited 50 % maximal effective concentration (EC50) at"/>
 <result pre="showed that hydroxychloroquine with or without azithromycin significantly reduced the" exact="viral" post="load and duration of virus shedding in 20 COVID-19"/>
 <result pre="are a serine protease inhibitor used in the treatment of" exact="chronic" post="pancreatitis and reflux esophagitis [14]. Ivermectin is a macrocyclic"/>
 <result pre="a serine protease inhibitor used in the treatment of chronic" exact="pancreatitis" post="and reflux esophagitis [14]. Ivermectin is a macrocyclic lactone"/>
 <result pre="protease inhibitor used in the treatment of chronic pancreatitis and" exact="reflux" post="esophagitis [14]. Ivermectin is a macrocyclic lactone used in"/>
 <result pre="inhibitor used in the treatment of chronic pancreatitis and reflux" exact="esophagitis" post="[14]. Ivermectin is a macrocyclic lactone used in the"/>
 <result pre="a macrocyclic lactone used in the treatment of various parasitic" exact="infections" post="[15]. However, data from well-designed randomized controlled trials for"/>
 <result pre="evaluate the individual drug compoundsâ€™ cell protection effects against SARS-CoV-2" exact="infection" post="[21]. Briefly, VeroE6 cells seeded in 96-well plates were"/>
 <result pre="infected with SARS-CoV-2 for 1 h with 0.01 multiplicity of" exact="infection" post="(MOI), followed by washing with phosphate-buffered saline (PBS) and"/>
 <result pre="2.3 ELISA ELISA was performed to determine the amount of" exact="viral" post="N protein expression in the culture supernatant of SARS-CoV-2-infected"/>
 <result pre="USA) for 2 h at 37 Â°C. After washing, the" exact="infectious" post="culture supernatants were transferred to the ELISA plates accordingly"/>
 <result pre="of another 50 Î¼L/well rabbit anti-SARS-CoV-N polyclonal antibody (1:4000), the" exact="secondary" post="goat-anti-rabbit horseradish peroxidase (HRP) antibody (1:1500, Invitrogen, Carlsbad, CA,"/>
 <result pre="plates for cell viability evaluation by CPE inhibition assay. 2.5" exact="Viral" post="load reduction assay Viral load reduction assay was performed"/>
 <result pre="evaluation by CPE inhibition assay. 2.5 Viral load reduction assay" exact="Viral" post="load reduction assay was performed on VeroE6 and Caco2"/>
 <result pre="for qRT-PCR analysis of virus replication. Briefly, 100 Î¼l of" exact="viral" post="supernatant was lyzed with 400 Î¼l of AVL buffer"/>
 <result pre="with 400 Î¼l of AVL buffer and then extracted for" exact="total" post="RNA with the QIAamp viral RNA mini kit (Qiagen,"/>
 <result pre="buffer and then extracted for total RNA with the QIAamp" exact="viral" post="RNA mini kit (Qiagen, Hilden, Germany). Real-time one-step qRT-PCR"/>
 <result pre="one-step qRT-PCR was used for quantitation of SARS-CoV-2 and SARS-CoV" exact="viral" post="load using the QuantiNova Probe RT-PCR kit (Qiagen) with"/>
 <result pre="at 37 Â°C in 5% CO2 before removal of unbound" exact="viral" post="particles by aspiration of the media and washing once"/>
 <result pre="Jersey, USA) in DMEM and appropriate concentrations of individual compound," exact="inverted" post="and incubated as above for another 72 h. The"/>
 <result pre="the virus replication cycle, including: pre-treatment (From -2 h post" exact="infection" post="(hpi) to -1 hpi), co-infection with virus (-1 to"/>
 <result pre="were labelled with the DAPI nucleic acid stain from Thermo" exact="Fisher" post="Scientific (Waltham, MA, USA). The Alexa Fluor secondary antibody"/>
 <result pre="from Thermo Fisher Scientific (Waltham, MA, USA). The Alexa Fluor" exact="secondary" post="antibody was obtained from Thermo Fisher Scientific. Mounting was"/>
 <result pre="USA). The Alexa Fluor secondary antibody was obtained from Thermo" exact="Fisher" post="Scientific. Mounting was performed with the Diamond Prolong Antifade"/>
 <result pre="was performed with the Diamond Prolong Antifade mountant from Thermo" exact="Fisher" post="Scientific. 3 Results 3.1 Characterization of SARS-CoV-2 replication kinetics"/>
 <result pre="a drug screening system for SARS-CoV-2, we first characterized the" exact="viral" post="replication kinetics of SARS-CoV-2 in VeroE6 cells and compared"/>
 <result pre="assay with CellTiterGloÂ® for evaluation of virus induced-cytopathic effects (CPE)," exact="viral" post="load quantitation assay with quantitative RT-PCR (qRT-PCR) targeting the"/>
 <result pre="viral load quantitation assay with quantitative RT-PCR (qRT-PCR) targeting the" exact="viral" post="RNA-dependent RNA polymerase (RdRp)/ helicase (Hel) genes, and viral"/>
 <result pre="the viral RNA-dependent RNA polymerase (RdRp)/ helicase (Hel) genes, and" exact="viral" post="nucleocapsid (N) protein expression with enzyme-linked immunosorbent assay (ELISA)."/>
 <result pre="observation of CPE development was recorded using different multiplicities of" exact="infection" post="(MOI) (1.000, 0.250, 0.063, 0.016, and 0.004). SARS-CoV-2 infection"/>
 <result pre="of infection (MOI) (1.000, 0.250, 0.063, 0.016, and 0.004). SARS-CoV-2" exact="infection" post="(MOI = 1.000) caused significant CPE in VeroE6 cells"/>
 <result pre="cells even with the lowest MOI of 0.004, while the" exact="morphology" post="of the non-infected VeroE6 cells remained intact. This observation"/>
 <result pre="with MOI of 0.016 or 0.004. In the qRT-PCR assay," exact="viral" post="RNA load in the culture supernatant markedly increased by"/>
 <result pre="and 1.000 MOI) (Fig. 1C). Regardless of the MOI, the" exact="viral" post="RNA load plateaued at 48 hpi. The viral N"/>
 <result pre="MOI, the viral RNA load plateaued at 48 hpi. The" exact="viral" post="N protein expression followed a delayed but similar pattern"/>
 <result pre="followed a delayed but similar pattern as that of the" exact="viral" post="RNA load, with the peak viral antigen expression being"/>
 <result pre="as that of the viral RNA load, with the peak" exact="viral" post="antigen expression being observed at 72 hpi (Fig. 1D)."/>
 <result pre="96-well plate were infected with SARS-CoV-2 of various multiplicities of" exact="infection" post="(MOIs)) as indicated, followed by phosphate buffered saline (PBS)"/>
 <result pre="culture supernatant was collected at the indicated time points with" exact="viral" post="copy number determined by quantitative RT-PCR (qRT-PCR). (D) The"/>
 <result pre="drug compound library The signal window is determined by the" exact="upper" post="and lower boundaries of the assay readout and is"/>
 <result pre="library The signal window is determined by the upper and" exact="lower" post="boundaries of the assay readout and is considered a"/>
 <result pre="2 ). Among the 1528 drug compounds, we identified 34" exact="primary" post="hit drug compounds with â‰¥4-fold reduction of detection signal"/>
 <result pre="with â‰¥4-fold reduction of detection signal in ELISA. In the" exact="secondary" post="screen by cell viability assay, 19 of these 34"/>
 <result pre="shown to exhibit anti-SARS-CoV-2 activity were also identified in our" exact="primary" post="screen with ELISA, but they showed &amp;gt;10 % CPE"/>
 <result pre="19 drug compound list. Camostat was not detected in the" exact="primary" post="screen but this might be related to its EC50"/>
 <result pre="EC50 being higher than 10Î¼M which was used in our" exact="primary" post="screen. Remdesivir was not included in the library and"/>
 <result pre="consisting 1528 drug compounds was screened for potential anti-SARS-CoV-2 agents." exact="Primary" post="screening by ELISA identified 34 drug compounds with 4-fold"/>
 <result pre="34 drug compounds with 4-fold reduction in the detection signal." exact="Secondary" post="screening by cell viability assay further selected 19 of"/>
 <result pre="for cytotoxicity and antiviral activity evaluation by plaque reduction and" exact="viral" post="load reduction assays. Table 1 Primary hit drug compounds"/>
 <result pre="by plaque reduction and viral load reduction assays. Table 1" exact="Primary" post="hit drug compounds identified from an FDA-approved drug library"/>
 <result pre="Drug class Main clinical use(s) Abiraterone (acetate) Synthetic androstane steroid" exact="Prostate cancer" post="Asenapine (hydrochloride) Atypical antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic"/>
 <result pre="class Main clinical use(s) Abiraterone (acetate) Synthetic androstane steroid Prostate" exact="cancer" post="Asenapine (hydrochloride) Atypical antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic"/>
 <result pre="use(s) Abiraterone (acetate) Synthetic androstane steroid Prostate cancer Asenapine (hydrochloride)" exact="Atypical" post="antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic syndrome and acute"/>
 <result pre="(acetate) Synthetic androstane steroid Prostate cancer Asenapine (hydrochloride) Atypical antipsychotic" exact="Schizophrenia" post="Azacytidine Nucleoside analogue Myelodysplastic syndrome and acute myeloid leukemia"/>
 <result pre="Prostate cancer Asenapine (hydrochloride) Atypical antipsychotic Schizophrenia Azacytidine Nucleoside analogue" exact="Myelodysplastic syndrome" post="and acute myeloid leukemia Bexarotene Retinoid (retinoid X receptor"/>
 <result pre="cancer Asenapine (hydrochloride) Atypical antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic" exact="syndrome" post="and acute myeloid leukemia Bexarotene Retinoid (retinoid X receptor"/>
 <result pre="(hydrochloride) Atypical antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic syndrome and" exact="acute" post="myeloid leukemia Bexarotene Retinoid (retinoid X receptor activator) Cutaneous"/>
 <result pre="Atypical antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic syndrome and acute" exact="myeloid leukemia" post="Bexarotene Retinoid (retinoid X receptor activator) Cutaneous T cell"/>
 <result pre="antipsychotic Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic syndrome and acute myeloid" exact="leukemia" post="Bexarotene Retinoid (retinoid X receptor activator) Cutaneous T cell"/>
 <result pre="and acute myeloid leukemia Bexarotene Retinoid (retinoid X receptor activator)" exact="Cutaneous" post="T cell lymphoma Candesartan (Cilexetil) Angiotensin receptor blocker Hypertension"/>
 <result pre="leukemia Bexarotene Retinoid (retinoid X receptor activator) Cutaneous T cell" exact="lymphoma" post="Candesartan (Cilexetil) Angiotensin receptor blocker Hypertension and congestive heart"/>
 <result pre="activator) Cutaneous T cell lymphoma Candesartan (Cilexetil) Angiotensin receptor blocker" exact="Hypertension" post="and congestive heart failure Cetilistat Pancreatic lipase inhibitor Obesity"/>
 <result pre="T cell lymphoma Candesartan (Cilexetil) Angiotensin receptor blocker Hypertension and" exact="congestive heart failure" post="Cetilistat Pancreatic lipase inhibitor Obesity Chloroquine (diphosphate) 4-Aminoquinoline Malaria"/>
 <result pre="cell lymphoma Candesartan (Cilexetil) Angiotensin receptor blocker Hypertension and congestive" exact="heart" post="failure Cetilistat Pancreatic lipase inhibitor Obesity Chloroquine (diphosphate) 4-Aminoquinoline"/>
 <result pre="blocker Hypertension and congestive heart failure Cetilistat Pancreatic lipase inhibitor" exact="Obesity" post="Chloroquine (diphosphate) 4-Aminoquinoline Malaria and amoebic liver abscess Ciclesonide"/>
 <result pre="heart failure Cetilistat Pancreatic lipase inhibitor Obesity Chloroquine (diphosphate) 4-Aminoquinoline" exact="Malaria" post="and amoebic liver abscess Ciclesonide Glucocorticoid Asthma and allergic"/>
 <result pre="Chloroquine (diphosphate) 4-Aminoquinoline Malaria and amoebic liver abscess Ciclesonide Glucocorticoid" exact="Asthma" post="and allergic rhinitis Diethylstilbestrol Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline"/>
 <result pre="4-Aminoquinoline Malaria and amoebic liver abscess Ciclesonide Glucocorticoid Asthma and" exact="allergic rhinitis" post="Diethylstilbestrol Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis"/>
 <result pre="Malaria and amoebic liver abscess Ciclesonide Glucocorticoid Asthma and allergic" exact="rhinitis" post="Diethylstilbestrol Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis"/>
 <result pre="abscess Ciclesonide Glucocorticoid Asthma and allergic rhinitis Diethylstilbestrol Nonsteroidal estrogen" exact="Prostate cancer" post="Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective serotonin reuptake"/>
 <result pre="Ciclesonide Glucocorticoid Asthma and allergic rhinitis Diethylstilbestrol Nonsteroidal estrogen Prostate" exact="cancer" post="Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective serotonin reuptake"/>
 <result pre="allergic rhinitis Diethylstilbestrol Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline Quinoline derivative" exact="Amoebiasis" post="Fluoxetine (hydrochloride) Selective serotonin reuptake inhibitor Depression Micafungin (sodium)"/>
 <result pre="Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine (hydrochloride)" exact="Selective" post="serotonin reuptake inhibitor Depression Micafungin (sodium) Echinocandin Fungal infection"/>
 <result pre="Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective serotonin reuptake inhibitor" exact="Depression" post="Micafungin (sodium) Echinocandin Fungal infection Permethrin Insecticide Scabies and"/>
 <result pre="Fluoxetine (hydrochloride) Selective serotonin reuptake inhibitor Depression Micafungin (sodium) Echinocandin" exact="Fungal" post="infection Permethrin Insecticide Scabies and lice Pimavanserin Atypical antipsychotic"/>
 <result pre="(hydrochloride) Selective serotonin reuptake inhibitor Depression Micafungin (sodium) Echinocandin Fungal" exact="infection" post="Permethrin Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s"/>
 <result pre="(sodium) Echinocandin Fungal infection Permethrin Insecticide Scabies and lice Pimavanserin" exact="Atypical" post="antipsychotic Parkinsonâ€™s disease psychosis Raloxifene (hydrochloride) Selective estrogen receptor"/>
 <result pre="infection Permethrin Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s" exact="disease" post="psychosis Raloxifene (hydrochloride) Selective estrogen receptor modulator Osteoporosis Sofalcone"/>
 <result pre="Permethrin Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease" exact="psychosis" post="Raloxifene (hydrochloride) Selective estrogen receptor modulator Osteoporosis Sofalcone Synthetic"/>
 <result pre="and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease psychosis Raloxifene (hydrochloride)" exact="Selective" post="estrogen receptor modulator Osteoporosis Sofalcone Synthetic sophoradin analogue Gastrointestinal"/>
 <result pre="antipsychotic Parkinsonâ€™s disease psychosis Raloxifene (hydrochloride) Selective estrogen receptor modulator" exact="Osteoporosis" post="Sofalcone Synthetic sophoradin analogue Gastrointestinal tract mucosal protection Tamoxifen"/>
 <result pre="Sofalcone Synthetic sophoradin analogue Gastrointestinal tract mucosal protection Tamoxifen (Citrate)" exact="Selective" post="estrogen receptor modulator Breast cancer, infertility, and gynecomastia Tilorone"/>
 <result pre="Gastrointestinal tract mucosal protection Tamoxifen (Citrate) Selective estrogen receptor modulator" exact="Breast" post="cancer, infertility, and gynecomastia Tilorone (dihydrochloride) Interferon inducer Antiviral"/>
 <result pre="Tamoxifen (Citrate) Selective estrogen receptor modulator Breast cancer, infertility, and" exact="gynecomastia" post="Tilorone (dihydrochloride) Interferon inducer Antiviral Tocofersolan Synthetic vitamin E"/>
 <result pre="(dihydrochloride) Interferon inducer Antiviral Tocofersolan Synthetic vitamin E Vitamin E" exact="deficiency" post="3.3In vitro antiviral evaluation of the selected drug compounds"/>
 <result pre="antiviral evaluation of the selected drug compounds Next, these 19" exact="primary" post="hit drug compounds were subjected to viral load reduction"/>
 <result pre="Next, these 19 primary hit drug compounds were subjected to" exact="viral" post="load reduction assay for prioritization based on their dose-dependent"/>
 <result pre="with any one of the four drug compounds below the" exact="non-toxic" post="drug concentration of 10Î¼M, markedly suppressed SARS-CoV-2-N protein expression"/>
 <result pre="in Fig. 5 A, all four drug compounds exhibited dose-dependent" exact="viral" post="load reduction with magnitudes of 1 log to 3"/>
 <result pre="EC50 of 1.04Î¼M in our study. Similar levels of dose-dependent" exact="viral" post="load reduction were observed in SARS-CoV-2-infected Caco2 (human colorectal"/>
 <result pre="culture supernatants and cell lysates (Fig. 5B). In addition to" exact="viral" post="load reduction, treatment with any one of these four"/>
 <result pre="demonstrated that cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene inhibited the" exact="viral" post="load, viral antigen expression, and infectious viral particle production"/>
 <result pre="cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene inhibited the viral load," exact="viral" post="antigen expression, and infectious viral particle production of SARS-CoV-2,"/>
 <result pre="and bexarotene inhibited the viral load, viral antigen expression, and" exact="infectious" post="viral particle production of SARS-CoV-2, and protected SARS-CoV-2-induced cell"/>
 <result pre="bexarotene inhibited the viral load, viral antigen expression, and infectious" exact="viral" post="particle production of SARS-CoV-2, and protected SARS-CoV-2-induced cell damages"/>
 <result pre="different concentrations of the selected drug compounds as indicated. The" exact="viral" post="load under each condition was collected at 48 hpi"/>
 <result pre="load under each condition was collected at 48 hpi for" exact="viral" post="load reduction assay by qRT-PCR. Intracellular viral loads were"/>
 <result pre="48 hpi for viral load reduction assay by qRT-PCR. Intracellular" exact="viral" post="loads were normalized by human Î²-actin. (C) VeroE6 cells"/>
 <result pre="to each drug compound at different time points, followed by" exact="viral" post="titer measurements at 9 hpi, when the first round"/>
 <result pre="with host cells or during virus adsorption (co-infection) significantly reduced" exact="viral" post="replication, suggesting that these three drug compounds disrupted the"/>
 <result pre="entry either by blocking the host ACE2 receptor or the" exact="viral" post="components required for cell attachment and entry. To further"/>
 <result pre="bexarotene did not block virus-host receptor binding, but significantly reduced" exact="viral" post="load during virus internationalization. These results suggested that bexarotene"/>
 <result pre="Time-of-drug-addition assay was performed to determine the steps of the" exact="viral" post="replication cycle targeted by each of the four identified"/>
 <result pre="drug compounds. The assay was conducted at 37 Â°C. (B)" exact="Viral" post="load in the treated VeroE6 cell culture supernatants normalized"/>
 <result pre="control. (C) Virus entry assay with or without bexarotene addition." exact="Viral" post="attachment was performed at 4â&quot;ƒ and then shifted to"/>
 <result pre="then shifted to 37â&quot;ƒ to enable virus internalization. (D) Intracellular" exact="viral" post="load in the treated VeroE6 cells normalized by DMSO"/>
 <result pre="the treated VeroE6 cells normalized by DMSO as control. (E)" exact="Viral" post="load reduction assay showing the dose-dependent anti-MERS-CoV activity of"/>
 <result pre="culture supernatant was then collected at 48 h post-inoculation for" exact="viral" post="load quantitation by qRT-PCR. *P indicates &amp;lt; 0.05 and"/>
 <result pre="blocks fat digestion and absorption used in the treatment of" exact="obesity" post="[28]. Diiodohydroxylquinoline, also known as uidoquinol, is a quinolone"/>
 <result pre="is used as a luminal amebicide for the treatment of" exact="amoebiasis" post="[29]. Cetilistat is rapidly hydrolyzed into its metabolites in"/>
 <result pre="COVID-19 patients develop gastrointestinal symptoms with some also having detectable" exact="viral" post="RNA and even infectious virus particles [31]. In a"/>
 <result pre="symptoms with some also having detectable viral RNA and even" exact="infectious" post="virus particles [31]. In a SARS-CoV-2-infected hamster model, it"/>
 <result pre="found that the animalsâ€™ intestines exhibited severe inflammation with detectable" exact="viral" post="RNA and abundant viral nucleocapsid protein expression [23]. These"/>
 <result pre="intestines exhibited severe inflammation with detectable viral RNA and abundant" exact="viral" post="nucleocapsid protein expression [23]. These findings showed that like"/>
 <result pre="in SARS, feces might also be a potential source of" exact="infection" post="in COVID-19 [2,32]. Thus, besides being administered by inhalation,"/>
 <result pre="might have a role as topical luminal antivirals to reduce" exact="viral" post="shedding in the gastrointestinal tract. Both abiraterone acetate and"/>
 <result pre="Both abiraterone acetate and bexarotene are non-chemotherapeutic antineoplastic drugs with" exact="limited" post="immunosuppressive effects. Abiraterone acetate is used in combination with"/>
 <result pre="acetate is used in combination with corticosteroid to treat refractory" exact="prostate cancer" post="through androgen deprivation by inhibition of the androgen synthesizing"/>
 <result pre="is used in combination with corticosteroid to treat refractory prostate" exact="cancer" post="through androgen deprivation by inhibition of the androgen synthesizing"/>
 <result pre="Bexarotene is a third-generation retinoid used in the treatment of" exact="cutaneous T cell lymphoma," post="non-small cell lung cancer, and breast cancer [[35], [36],"/>
 <result pre="in the treatment of cutaneous T cell lymphoma, non-small cell" exact="lung cancer," post="and breast cancer [[35], [36], [37], [38]]. We showed"/>
 <result pre="of cutaneous T cell lymphoma, non-small cell lung cancer, and" exact="breast cancer" post="[[35], [36], [37], [38]]. We showed that abiraterone acetate"/>
 <result pre="cutaneous T cell lymphoma, non-small cell lung cancer, and breast" exact="cancer" post="[[35], [36], [37], [38]]. We showed that abiraterone acetate"/>
 <result pre="achieve Cmax (Tmax) with standard oral dosing of bexarotene is" exact="short" post="(2.5 h), which is important especially in COVID-19 patients"/>
 <result pre="for conducting drug discovery programmes for COVID-19. The topical and/or" exact="systemic" post="effects of cetilistat, diiodohydroxylquinoline, abiraterone acetate, and bexarotene should"/>
 <result pre="and was an invited speaker for Gilead Sciences Hong Kong" exact="Limited" post="and Luminex Corporation. The other authors declared no conflict"/>
 <result pre="of novel viruses: lessons from bats and birdsTrends Microbiol.21201354455523770275 2ChengV.C.LauS.K.WooP.C.YuenK.Y.Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
 <result pre="novel viruses: lessons from bats and birdsTrends Microbiol.21201354455523770275 2ChengV.C.LauS.K.WooP.C.YuenK.Y.Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
 <result pre="viruses: lessons from bats and birdsTrends Microbiol.21201354455523770275 2ChengV.C.LauS.K.WooP.C.YuenK.Y.Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infectionClin."/>
 <result pre="agent of emerging and reemerging infectionClin. Microbiol. Rev.20200766069417934078 3ChanJ.F.LauS.K.ToK.K.ChengV.C.WooP.C.YuenK.Y.Middle East" exact="respiratory" post="syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseClin. Microbiol."/>
 <result pre="of emerging and reemerging infectionClin. Microbiol. Rev.20200766069417934078 3ChanJ.F.LauS.K.ToK.K.ChengV.C.WooP.C.YuenK.Y.Middle East respiratory" exact="syndrome" post="coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseClin. Microbiol. Rev.28201546552225810418"/>
 <result pre="SARS-like diseaseClin. Microbiol. Rev.28201546552225810418 4ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N. Engl. J. Med.382202072773331978945 5World Health OrganizationCoronavirus"/>
 <result pre="Pneumonia in China, 2019N. Engl. J. Med.382202072773331978945 5World Health OrganizationCoronavirus" exact="Disease" post="2019 (COVID-19) Situation Report â€&quot; 772020https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200406-sitrep-77-covid-19.pdf?sfvrsn=21d1e632_2 6ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.A familial cluster"/>
 <result pre="Health OrganizationCoronavirus Disease 2019 (COVID-19) Situation Report â€&quot; 772020https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200406-sitrep-77-covid-19.pdf?sfvrsn=21d1e632_2 6ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="2019 (COVID-19) Situation Report â€&quot; 772020https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200406-sitrep-77-covid-19.pdf?sfvrsn=21d1e632_2 6ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.XingF.LiuJ.YipC.C.PoonR.W.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="Dis.2020ciaa19810.1093/cid/ciaa198[Epub ahead of print]32112072 8VerityR.OkellL.C.DorigattiI.WinskillP.WhittakerC.ImaiN.Cuomo-DannenburgG.ThompsonH.WalkerP.G.T.FuH.Estimates of the severity of coronavirus" exact="disease" post="2019: a model-based analysisLancet Infect. Dis.202010.1016/S1473-3099(20)30243-7pii: S1473-3099(20)30243-7. [Epub ahead"/>
 <result pre="Dis.202010.1016/S1473-3099(20)30243-7pii: S1473-3099(20)30243-7. [Epub ahead of print] 9GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.LiuL.ShanH.LeiC.L.HuiD.S.C.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN. Engl. J. Med.202010.1056/NEJMoa2002032[Epub ahead of print]"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020ciaa23710.1093/cid/ciaa237[Epub ahead of"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020ciaa23710.1093/cid/ciaa237[Epub ahead of print]"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020ciaa23710.1093/cid/ciaa237[Epub ahead of print] 17ChuH.ChanJ.F.YuenT.T.ShuaiH.YuanS.WangY.HuB.YipC.C.TsangJ.O.HuangX.An"/>
 <result pre="18ZakiA.M.van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN. Engl. J. Med.367201318141820 19ChanJ.F.ChanK.H.ChoiG.K.ToK.K.TseH.CaiJ.P.YeungM.L.ChengV.C.ChenH.CheX.Y.Differential cell line"/>
 <result pre="pneumonia in Saudi ArabiaN. Engl. J. Med.367201318141820 19ChanJ.F.ChanK.H.ChoiG.K.ToK.K.TseH.CaiJ.P.YeungM.L.ChengV.C.ChenH.CheX.Y.Differential cell line" exact="susceptibility to" post="the emerging novel human betacoronavirus 2c EMC/2012: implications for"/>
 <result pre="to the emerging novel human betacoronavirus 2c EMC/2012: implications for" exact="disease" post="pathogenesis and clinical manifestationJ. Infect. Dis.20720131743175223532101 20ChuH.ChanJ.F.WangY.YuenT.T.ChaiY.HouY.ShuaiH.YangD.HuB.HuangX.Comparative replication and"/>
 <result pre="as a broad-spectrum antiviral targetNat. Commun.10201912030631056 22CheX.Y.QiuL.W.LiaoZ.Y.WangY.D.WenK.PanY.X.HaoW.MeiY.B.ChengV.C.YuenK.Y.Antigenic cross-reactivity between severe" exact="acute" post="respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43J."/>
 <result pre="a broad-spectrum antiviral targetNat. Commun.10201912030631056 22CheX.Y.QiuL.W.LiaoZ.Y.WangY.D.WenK.PanY.X.HaoW.MeiY.B.ChengV.C.YuenK.Y.Antigenic cross-reactivity between severe acute" exact="respiratory" post="syndrome-associated coronavirus and human coronaviruses 229E and OC43J. Infect."/>
 <result pre="Dis.19120052033203715897988 23ChanJ.F.ZhangA.J.YuanS.PoonV.K.ChanC.C.LeeA.C.ChanW.M.FanZ.TsoiH.W.WenL.Simulation of the clinical and pathological manifestations of Coronavirus" exact="Disease" post="2019 (COVID-19) in golden Syrian hamster model: implications for"/>
 <result pre="Disease 2019 (COVID-19) in golden Syrian hamster model: implications for" exact="disease" post="pathogenesis and transmissibilityClin. Infect. Dis.2020ciaa32510.1093/cid/ciaa325[Epub ahead of print]32215622 24ChanJ.F.ChanK.H.KaoR.Y.ToK.K.ZhengB.J.LiC.P.LiC.P.T.DaiJ.MokF.K.ChenH.Broad-spectrum"/>
 <result pre="ahead of print]32215622 24ChanJ.F.ChanK.H.KaoR.Y.ToK.K.ZhengB.J.LiC.P.LiC.P.T.DaiJ.MokF.K.ChenH.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect.67201360661624096239 25YuanS.ChuH.ZhaoH.ZhangK.SinghK.ChowB.K.KaoR.Y.ZhouJ.ZhengB.J.Identification of a small-molecule inhibitor of"/>
 <result pre="of print]32215622 24ChanJ.F.ChanK.H.KaoR.Y.ToK.K.ZhengB.J.LiC.P.LiC.P.T.DaiJ.MokF.K.ChenH.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect.67201360661624096239 25YuanS.ChuH.ZhaoH.ZhangK.SinghK.ChowB.K.KaoR.Y.ZhouJ.ZhengB.J.Identification of a small-molecule inhibitor of influenza"/>
 <result pre="of influenza virus via disrupting the subunits interaction of the" exact="viral" post="polymeraseAntiviral Res.1252016344226593979 26ChanJ.F.YipC.C.ToK.K.TangT.H.WongS.C.LeungK.H.FungA.Y.NgA.C.ZouZ.TsoiH.W.Improved molecular diagnosis of COVID-19 by the"/>
 <result pre="small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits" exact="viral" post="replicationJ. Antimicrob. Chemother.7120162489249727272726 28BrysonA.de la MotteS.DunkC.Reduction of dietary fat"/>
 <result pre="cetilistat in healthy volunteersBr. J. Clin. Pharmacol.67200930931519220279 29RickardsA.G.The treatment of" exact="amoebiasis" post="with diodoquinJ. Trop. Med. Hyg.521949333818111812 30PadwalR.Cetilistat, a new lipase"/>
 <result pre="treatment of obesityCurr. Opin. Investig. Drugs92008414421 31CheungK.S.HungI.F.ChanP.P.LungK.C.TsoE.LiuR.NgY.Y.ChuM.Y.ChungT.W.TamA.R.Gastrointestinal manifestations of SARS-CoV-2" exact="infection" post="and virus load in fecal samples from the Hong"/>
 <result pre="34ArasaratnamM.CrumbakerM.BhatnagarA.McKayMjMolloyMpGurneyH.Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in" exact="metastatic" post="prostate cancerCancer Chemother. Pharmacol.84201913914631081533 35BoehmM.F.ZhangL.ZhiL.McClurgM.R.BergerE.WagonerM.MaisD.E.SutoC.M.Design and synthesis of potent"/>
 <result pre="potent retinoid X receptor selective ligands that induce apoptosis in" exact="leukemia" post="cellsJ. Med. Chem.381995314631557636877 36GniadeckiR.AssafC.BagotM.DummerR.DuvicM.KnoblerR.RankiA.SchwandtP.WhittakerS.The optimal use of bexarotene in"/>
 <result pre="leukemia cellsJ. Med. Chem.381995314631557636877 36GniadeckiR.AssafC.BagotM.DummerR.DuvicM.KnoblerR.RankiA.SchwandtP.WhittakerS.The optimal use of bexarotene in" exact="cutaneous" post="T-cell lymphomaBr. J. Dermatol.157200743344017553039 37DragnevK.H.PettyW.J.ShahS.J.LewisL.D.BlackC.C.MemoliV.NugentW.C.HermannT.Negro-VilarA.RigasJ.R.A proof-of-principle clinical trial of"/>
 <result pre="trial of bexarotene in patients with non-small cell lung cancerClin." exact="Cancer" post="Res.1320071794180017363535 38EstevaF.J.GlaspyJ.BaidasS.LaufmanL.HutchinsL.DicklerM.TripathyD.CohenR.Multicenter phase II study of oral bexarotene for"/>
 <result pre="38EstevaF.J.GlaspyJ.BaidasS.LaufmanL.HutchinsL.DicklerM.TripathyD.CohenR.Multicenter phase II study of oral bexarotene for patients with" exact="metastatic" post="breast cancerJ. Clin. Oncol.212003999100612637463 39ListonD.R.DavisM.Clinically relevant concentrations of anticancer"/>
 <result pre="phase II study of oral bexarotene for patients with metastatic" exact="breast" post="cancerJ. Clin. Oncol.212003999100612637463 39ListonD.R.DavisM.Clinically relevant concentrations of anticancer drugs:"/>
 <result pre="relevant concentrations of anticancer drugs: a guide for nonclinical studiesClin." exact="Cancer" post="Res.2320173489349828364015 Acknowledgements This study was partly supported by funding"/>
 <result pre="Hong Kong, Michael Seak-Kan Tong, May Tam Mak Mei Yin," exact="Respiratory" post="Viral Research Foundation Limited, Hui Ming, Hui Hoy and"/>
 <result pre="Kong, Michael Seak-Kan Tong, May Tam Mak Mei Yin, Respiratory" exact="Viral" post="Research Foundation Limited, Hui Ming, Hui Hoy and Chow"/>
</results>
